The following is a summary of the Delcath Systems Inc (DCTH) Q4 2023 Earnings Call Transcript:

Financial Performance:

• Delcath Systems Inc. ended Q4 2023 with $32.5 million in cash and investments.

• Revenue from their sales of CHEMOSAT was $0.5 million for Q4 2023, a slight decrease from the same period in 2022.

• Research and development expenses rose slightly to $4.7 million in Q4 2023, mainly due to increased personnel expenses.

• Selling, general, and administrative expenses for Q4 2023 were $7 million, almost double that of Q4 2022, as the company prepared for the commercial launch of the HEPZATO KIT.

• A $7 million private placement financing has been closed, potentially providing additional $25 million proceeds presuming the company reaches a $10 million quarterly revenue by no later than Q4 2024.

Business Progress:

• Delcath Systems Inc. is making good progress with the sales of HEPZATO KIT across the US and expects to activate more sites by the end of 2024.

• Demonstrating potential, the first commercial patient treatment at Moffitt Cancer Center took place in January 2024.

• R&D continues, as Delcath has plans over the next year to study the efficacy of HEPZATO KIT in treating a variety of liver cancers.

• The company has initiated the European CHOPIN trial, with results expected in Q2 2025.

• Trained clinicians have reached approximately 90 across various sites and a similar number of preceptorships are expected to aid in the activation of 20 sites by year-end.

• Delcath is investing in improving referral networks and reimbursement processes to refine its business strategy.

More details: Delcath Systems IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.